Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech has confirmed the clinically and statistically significant improvement in the primary endpoint of progression free survival for the two different doses of Avastin studied in the Phase III non-small cell lung cancer trial compared to chemotherapy alone.
Subscribe to our email newsletter
But the study did not demonstrate a statistically significant prolongation of overall survival, a secondary endpoint, for either dose in combination with gemcitabine and cisplatin chemotherapy compared to chemotherapy alone.
Median survival of patients in all arms of the study exceeded one year, longer than previously reported survival times in this indication. No new safety signals for Avastin were observed in the study, and there were no clinically meaningful differences in safety between the two doses of Avastin.
Hal Barron, senior vice president, development and chief medical officer, Genentech, said: “These studies reinforce our belief that Avastin is an important treatment option for patients with this most common form of lung cancer.”